Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

KACST Partners with Life Tech in The Saudi Human Genome Program

Published: Monday, December 09, 2013
Last Updated: Monday, December 09, 2013
Bookmark and Share
Program aims to analyze 100,000 human genomes to identify the causes of disease in the population of the Kingdom of Saudi Arabia and the Arab world.

The King Abdulaziz City for Science and Technology (KACST), Saudi Arabia's national funding agency, and Life Technologies Corporation  announce The Saudi Human Genome Program — a national research project to study the genetic basis of all disease in the Kingdom and throughout the Middle East and use the findings to offer the ultimate personal care in Saudi Arabia.

Through a network of an initial 10 genome centers across Saudi Arabia, the ambitious program using the Ion Proton™  DNA sequencer,  will focus on sequencing 100,000 human genomes over the next five years to study both normal and disease-associated genes specific to the Saudi population, with five further genome centers to be created in the future.  This genomic variant data will be fully analyzed and used to create a Saudi-specific database that will provide the basis for future development of personalized medicine in the Kingdom and represents the most comprehensive effort to identify the disease-causing genes for the population of a country and Arab peoples.

"King Abdulaziz City for Science and Technology is committed to the development of R&D programs of excellence in all scientific disciplines," said Dr.Mohammed Bin Ibrahim Al Suwayl, President of KACST. "We have clear strategy and policy of the importance of science to a knowledge-based society and we believe the Saudi Human Genome Program will help shape the understanding of health and disease and usher in an era of personalized medicine in the Kingdom of Saudi Arabia and we are grateful for the investment and vision of the Saudi leadership."

Prince Dr. Turki bin Saud Al Saud, KACST Vice President for Research Institutes said: "The Saudi Human Genome Program will position the Kingdom at the forefront of personalized medicine and will empower our citizens to help them make informed decisions for their health plans. It's hoped other global academic institutions will use the impressive facilities KACST is launching in the near future."

The sequencing will be performed using Life Technologies' semiconductor-based Ion Proton™ DNA sequencer. The instruments will be deployed in the network of 15 genome centers at various sites across the Kingdom.  

"This is a program of exceptional scale enabled by the Ion Proton," said Gregory T. Lucier, Chairman and Chief Executive Officer of Life Technologies. "It demonstrates KACST's vision to position the Kingdom of Saudi Arabia as a world leader in genetic research through its genome centers to deliver the ultimate in personalized medicine.  We expect the Saudi Human Genome Program will provide a model which many countries will follow."

Each center is designed and equipped by Life Technologies' Enterprise Genomics Services team which will further accelerate the project by providing end-to-end solutions and services for operations and informatics. This wealth of information, provided with the full consent of participants, will also enable clinicians in the future to offer premarital and prenatal screening for rare diseases, which will facilitate preventive medicine and decrease the emotional, social and economic burden of rare birth defects. The data will also enable worldwide population studies to understand and compare population-specific influences leading to normal and harmful variants, common and rare mutations.

Dr. Prabhu Sampath, Chief Executive Officer of Life Technologies' distributor in the Middle East, Integrated Gulf Biosystems (IGB) said: "IGB is privileged to have played a pivotal role in bringing this disruptive technology in genome sequencing from Life Technologies to KACST and the impact of this project will be far reaching and will lead to the introduction of new techniques and tools, including precision medicine to both patients and the clinicians treating them."

The Ion Proton™ is For Research Use Only. Not for use in diagnostic procedures.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Life Technologies Awards Digital PCR Innovation Grants to Five Research Labs
The five Innovation Grant recipients in the Digital PCR Applications Grant Program was announced during the ASHG conference in Boston.
Thursday, October 24, 2013
Thermo Acquisition Approved by Life Technologies Stockholders
Company announced that its stockholders voted to adopt the previously announced merger agreement.
Thursday, August 22, 2013
Life Technologies Enters into an Exclusive License and Supply Agreement for Dynabead
Life Technologies has signed a long-term supply and exclusive licensing agreement with Novartis for immunotherapeutics involving T cells modified to express chimeric antigen receptors for the treatment of cancer.
Thursday, August 01, 2013
Life Technologies Announces Second Quarter 2013 Results
Revenue increased 1% excluding impact of currency.
Thursday, August 01, 2013
Life Technologies Signs Five-Year Agreement with the FDA
The agreement aims to accelerate and advance food safety testing of E. coli and Salmonella, two foodborne contaminants commonly associated with outbreaks and/or recalls.
Tuesday, July 30, 2013
Roswell Park Cancer Institute Purchases Six Ion Torrent Sequencers
Life Technologies Corporation announced that the new Center for Personalized Medicine at Roswell Park Cancer Institute has purchased four Ion Proton™ sequencers and two Ion Personal Genome Machine™ sequencers.
Thursday, February 21, 2013
Boston Children's Hospital and Life Technologies Launch Claritas Genomics, a Clinical Genomics Company
Spinoff venture will develop genomic sequencing solutions utilizing Ion Torrent technology for clinical applications.
Thursday, January 10, 2013
Life Technologies introduces Ion AmpliSeq™ Community Panels
Ion AmpliSeq™ Community Panels leverages the expertise of scientific thought leaders and the Ion Community to create gene panels for conditions ranging from cancer to inherited diseases.
Wednesday, November 07, 2012
Life Technologies Acquires Compendia Bioscience
Acquisition expands Life Technologies' ability to drive progress in personalized medicine
Sunday, October 14, 2012
Life Technologies Acquires Compendia Bioscience
Bioinformatics expertise will enable deeper engagement with established customer base of leading pharmaceutical companies.
Tuesday, October 09, 2012
Life Technologies Signs Collaborative Agreement with Structural Genomics Consortium
Pioneering joint venture releases 58 of 200 planned, highly-specific recombinant antibodies for epigenetic studies.
Thursday, July 19, 2012
Life Technologies Collaborate with University of North Texas Health Science Center
University of North Texas Health Science Center advances forensic research by investing in semiconductor DNA sequencing technology.
Thursday, June 21, 2012
SickKids Adopts Life Technologies' Ion Proton™ Sequencer to Launch New Centre for Genetic Medicine
Long-term partnership will focus on sequencing 10,000 genomes per year to revolutionize pediatric disease research in Canada.
Thursday, June 21, 2012
Life Technologies Teams with Universitry of North Texas
University Advances Forensic Research by Investing in Semiconductor DNA Sequencing Technology.
Thursday, June 21, 2012
Celebrating the 10th Anniversary of the Human Genome Project's Completion
Life Technologies Foundation announces lead sponsorship of Smithsonian exhibit.
Tuesday, May 22, 2012
Scientific News
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Searching Big Data Faster
Theoretical analysis could expand applications of accelerated searching in biology, other fields.
Growing Hepatitis C in the Lab
Recent discovery allows study of naturally occurring forms of hepatitis C virus (HCV) in the lab.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Reprogramming Cancer Cells
Researchers on Mayo Clinic’s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
How DNA ‘Proofreader’ Proteins Pick and Edit Their Reading Material
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have discovered how two important proofreader proteins know where to look for errors during DNA replication and how they work together to signal the body’s repair mechanism.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!